Inhibrx Biosciences (INBX) FCF Margin (2023 - 2025)
Historic FCF Margin for Inhibrx Biosciences (INBX) over the last 3 years, with Q2 2025 value amounting to 2304.08%.
- Inhibrx Biosciences' FCF Margin rose 562689200.0% to 2304.08% in Q2 2025 from the same period last year, while for Sep 2025 it was 11127.93%, marking a year-over-year increase of 77893900.0%. This contributed to the annual value of 98503.0% for FY2024, which is 875084400.0% down from last year.
- Per Inhibrx Biosciences' latest filing, its FCF Margin stood at 2304.08% for Q2 2025, which was up 562689200.0% from 1335.66% recorded in Q1 2025.
- Inhibrx Biosciences' FCF Margin's 5-year high stood at 1335.66% during Q1 2025, with a 5-year trough of 58573.0% in Q2 2024.
- In the last 3 years, Inhibrx Biosciences' FCF Margin had a median value of 3688.07% in 2023 and averaged 21748.34%.
- As far as peak fluctuations go, Inhibrx Biosciences' FCF Margin tumbled by -400479300bps in 2024, and later skyrocketed by 562689200bps in 2025.
- Inhibrx Biosciences' FCF Margin (Quarter) stood at 3688.07% in 2023, then plummeted by -1086bps to 43736.0% in 2024, then skyrocketed by 95bps to 2304.08% in 2025.
- Its FCF Margin was 2304.08% in Q2 2025, compared to 1335.66% in Q1 2025 and 43736.0% in Q4 2024.